Marie-Claude Robert1, Samer N Arafat, Sandra Spurr-Michaud, James Chodosh, Claes H Dohlman, Ilene K Gipson. 1. *Department of Ophthalmology, Schepens Eye Research Institute, Massachusetts Eye and Ear Infirmary, Harvard Medical School, Boston, MA; †Department of Ophthalmology, Massachusetts Eye and Ear Infirmary, Harvard Medical School, Boston, MA; and ‡Department of Ophthalmology, Centre Hospitalier de l'Université de Montréal, Université de Montréal, Montréal, QC, Canada.
Abstract
PURPOSE: To investigate the tear levels of matrix metalloproteinases (MMPs), myeloperoxidase (MPO), and tissue inhibitor of metalloproteinase-1 in eyes after Boston keratoprosthesis type I (B-KPro) implantation and to correlate these markers with the established B-KPro prognostic categories. METHODS: Tear washes were collected from 40 patients (7 with autoimmune disease, 2 with chemical burn, and 31 with other noncicatrizing diagnoses). Tear levels of MMPs, MPO, and tissue inhibitor of metalloproteinase-1 were quantified using multianalyte bead-based enzyme-linked immunosorbent assays. The total MMP activity was determined using a fluorimetric assay. The analytes were compared to the underlying diagnosis and other clinical factors. RESULTS: The MMP-8, MMP-9, and MPO levels were markedly elevated in the eyes with B-KPro (80 ± 31, 291 ± 77, and 244 ± 33 pg/μg, respectively). Chemical burn was associated with significantly higher tear MMP-8 (474 ± 376 pg/μg) and MMP-9 levels (1300 ± 635 pg/μg) compared with noncicatrizing diseases (MMP-8: 41 ± 15 pg/μg, P = 0.02 and MMP-9: 196 ± 57 pg/μg, P = 0.02) and higher MMP-9 levels compared with autoimmune diseases (MMP-8: 96 ± 65 pg/μg, P = 0.21 and MMP-9: 306 ± 196 pg/μg, P = 0.04). Similar analyte levels were observed in the B-KPro eye and the contralateral non-B-KPro eye of patients with bilateral diseases. MMP-8, MMP-9, and total MMP activities correlated strongly with each other. CONCLUSIONS: In the eyes with B-KPro, tear MMP-8 and MMP-9 levels seem to be related to the underlying ocular surface pathology and not significantly influenced by the presence of the prosthesis.
PURPOSE: To investigate the tear levels of matrix metalloproteinases (MMPs), myeloperoxidase (MPO), and tissue inhibitor of metalloproteinase-1 in eyes after Boston keratoprosthesis type I (B-KPro) implantation and to correlate these markers with the established B-KPro prognostic categories. METHODS: Tear washes were collected from 40 patients (7 with autoimmune disease, 2 with chemical burn, and 31 with other noncicatrizing diagnoses). Tear levels of MMPs, MPO, and tissue inhibitor of metalloproteinase-1 were quantified using multianalyte bead-based enzyme-linked immunosorbent assays. The total MMP activity was determined using a fluorimetric assay. The analytes were compared to the underlying diagnosis and other clinical factors. RESULTS: The MMP-8, MMP-9, and MPO levels were markedly elevated in the eyes with B-KPro (80 ± 31, 291 ± 77, and 244 ± 33 pg/μg, respectively). Chemical burn was associated with significantly higher tear MMP-8 (474 ± 376 pg/μg) and MMP-9 levels (1300 ± 635 pg/μg) compared with noncicatrizing diseases (MMP-8: 41 ± 15 pg/μg, P = 0.02 and MMP-9: 196 ± 57 pg/μg, P = 0.02) and higher MMP-9 levels compared with autoimmune diseases (MMP-8: 96 ± 65 pg/μg, P = 0.21 and MMP-9: 306 ± 196 pg/μg, P = 0.04). Similar analyte levels were observed in the B-KPro eye and the contralateral non-B-KPro eye of patients with bilateral diseases. MMP-8, MMP-9, and total MMP activities correlated strongly with each other. CONCLUSIONS: In the eyes with B-KPro, tear MMP-8 and MMP-9 levels seem to be related to the underlying ocular surface pathology and not significantly influenced by the presence of the prosthesis.
Authors: Royce Mohan; Shravan K Chintala; Jae Chang Jung; Winston V L Villar; Frank McCabe; Laoti A Russo; Yunhee Lee; Brendan E McCarthy; Kurt R Wollenberg; James V Jester; Min Wang; Howard G Welgus; J Michael Shipley; Robert M Senior; M Elizabeth Fini Journal: J Biol Chem Date: 2001-10-31 Impact factor: 5.157
Authors: Alja Crnej; Masahiro Omoto; Thomas H Dohlman; Claes H Dohlman; Reza Dana Journal: Invest Ophthalmol Vis Sci Date: 2014-12-16 Impact factor: 4.799
Authors: Joseph B Ciolino; Michael W Belin; Amit Todani; Khalid Al-Arfaj; Christopher J Rudnisky Journal: Ophthalmology Date: 2013-03-15 Impact factor: 12.079
Authors: Samer N Arafat; Ana M Suelves; Sandra Spurr-Michaud; James Chodosh; C Stephen Foster; Claes H Dohlman; Ilene K Gipson Journal: Ophthalmology Date: 2013-08-17 Impact factor: 12.079
Authors: Valerie Yu; Dhruva Bhattacharya; Andrew Webster; Aditi Bauskar; Charles Flowers; Martin Heur; Shravan K Chintala; Tatsuo Itakura; Mark R Wilson; Joseph T Barr; Shinwu Jeong; Mingwu Wang; M Elizabeth Fini Journal: Ocul Surf Date: 2018-08-02 Impact factor: 5.033